Subscribe by Email

About the Blog

The Active Ingredient features expert insights and commentary from leaders of ZS Associates' global pharmaceuticals practice.

Search by Topic

see all

The Keys to Pharma’s AI Success Include ‘Disruptive Collaborations’ and a Willingness to Innovate and Iterate

Posted by Pratap Khedkar on Wed, Jan 24, 2018

This is the final post in a three-part series on artificial intelligence in healthcare. 

Of all of the marketplace dynamics and advances currently posing a threat to pharma’s traditional methods and models, artificial intelligence and advanced data science are causing their fair share of consternation. I recently addressed this issue with my colleague John Piccone, a ZS principal and advanced data science expert who previously led IBM Watson Health’s life sciences offerings, and he succinctly stated the commercial transformation challenge that lies ahead: “Pharma’s role is going to change from educating people to educating algorithms.” How can pharma get there? What steps can companies start taking now to adapt? John has some ideas.

Read More

Topics: patient outcomes, outcomes, artificial intelligence, commercial strategy, pharma companies, artificial intelligence & pharma, educate algorithms, innovators, traditional model, AI blog series

AI Will Usher in ‘Dramatic’ Changes to Pharma’s Commercial Model

Posted by Pratap Khedkar on Thu, Jan 18, 2018

This is the second post in a three-part series on artificial intelligence in healthcare. 

Artificial intelligence is poised to revolutionize the healthcare ecosystem. Providers are starting to apply AI in an effort to leverage patient data, therapy information and standards of care to make better treatment decisions. Payers are experimenting with AI to help with pre-authorization and claims adjudication. Whether or not the pharma industry is ready, AI is changing the way that pharma’s customers and stakeholders do business, thereby necessitating changes to pharma’s own commercial practices. And, according to my colleague John Piccone, those changes will be “dramatic.”

Read More

Topics: Big Pharma, healthcare ecosystem, AI, commercial strategy, artificial intelligence & pharma, pre-authorization, educate algorithms, treatment decisions, clinical decision support, claims, AI blog series

Subscribe to The Active Ingredient


Subscribe to receive email notifications whenever new blog posts are published.